PCDH11X

Across TCGA pan-cancer cohorts, PCDH11X Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PCDH11X data layer compared with 21 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PCDH11X Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated PCDH11X expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, KIRP, and READ are the cancer types where PCDH11X Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.928	0.410	<.001	36	view →
KIRP	OS	Median	All	0.178	0.885	<.001	18	view →
READ	DFS	Median	IV	0.183	0.639	.002	12	view →
LGG	OS	Median	All	0.552	0.889	.001	11	view →
CESC	DFS	Median	III,IV	0.217	0.634	.044	6	view →
PRAD	DFS	Median	All	0.759	0.935	.019	6	view →
GBM	OS	Median	All	0.171	0.420	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PCDH11X–UCEC (DFS)

Open the UCEC breakdown →